# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announ...
RBC Capital analyst Conor McNamara reiterates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and maintains $401 price tar...
RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target f...
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from...
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $3.11 per share which beat the analyst consensus estimate of $2....
The market's resilient run has made traders cautious of a potential correction, but analysts remain optimistic about its tr...
Jefferies assumes Bio-Rad Laboratories (NYSE:BIO) with a Hold rating and lowers Price Target of $315.
-Reuters